Navigation Links
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Date:12/17/2007

one of two treatment arms:

-- Treatment arm A received dose-dense combination of doxorubicin and

cyclophosphamide with Avastin, followed by paclitaxel and Avastin,

followed by Avastin alone. Avastin was given every 2 weeks at a dose

of 10 mg/kg for 1 year.

-- Treatment arm B was only different to arm A in that Avastin was

introduced after completion of doxorubicin therapy in conjunction with

paclitaxel. As with arm A, patients remained on Avastin for 1 year

after Avastin initiation.

The primary objective of the study was to determine the incidence of clinically apparent cardiac dysfunction in patients with lymph node positive breast cancer treated with bevacizumab and dose dense doxorubicin/cyclophosphamide followed by paclitaxel (ddAC>T). Patients were evaluated clinically and with serial assessments of left ventricular function over the course of their treatment and for six months following treatment.

Additional information

-- Roche in Oncology:

http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

-- Roche Health Kiosk, Cancer:

http://www.health-kiosk.ch/start_krebs

References:

(1) Miller KD, et al. E2100 Breast Cancer Res Treat 2005;94:S6

(Abstract 3)

(2) Kamangar F, et al. J Clin Oncol 2006; 24(14): 2137-50.


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 1Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 2Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 3Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 1Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 2Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 3SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 1SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 2SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 3
Other Medicine News:Health News:Americans United for Life Condemns Ruling Increasing Minors' Access to Dangerous Plan B 2Health News:AANS President to Testify on Patient Access to Care 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 3Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 4Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 5Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 6Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 7Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 8Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 9Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 10Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 11Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 12Health News:Young Survival Coalition and Living Beyond Breast Cancer Announce Support for Rep. Wasserman Schultz's 'The Early Act' 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3